COX -

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • GlobeNewswire

    Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis

    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's Investigational New Drug (IND) application for NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatment of the eyelid margin for patients with acute exacerbations of blepharitis.  The IND was submitted to the U.S. FDA in December 2018 ahead of the target of the first quarter of 2019. The IND is now in effect and we look forward to announcing the start of the first-in-human, randomized, placebo-controlled, Phase 2 clinical trial for patients with acute exacerbations of blepharitis, which is expected to report top-line results in the second half of 2019.

  • GlobeNewswire

    Nicox Establishes High-Profile Glaucoma Clinical Advisory Board

    Press Release Nicox Establishes High-Profile Glaucoma Clinical Advisory Board ............................................... Key U.S. clinical investigators and.

  • GlobeNewswire

    Nicox extends cash runway beyond 2020 with bond financing from Kreos Capital of up to €20 million

    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced it has entered into a bond financing for up to €20 million from Kreos Capital. This financing of up to €20 million, structured as bonds, consist of 3 tranches.  The first tranche of €8 million will be drawn down on or about February 1st , 2019, and the company has the option, but no obligation, to draw down a further maximum amount of €7 million on August 1st, 2019, and a maximum amount of €5 million on November 1st, 2019.

  • GlobeNewswire

    Nicox Fourth Quarter 2018 Business Update and Financial Highlights

    Press Release Nicox Fourth Quarter 2018 Business Update and Financial Highlights ............................................... Total VYZULTA®.

  • GlobeNewswire

    Nicox Reaches 50% Enrollment Threshold in U.S. Phase 2 Study with NCX 470 Ahead of Schedule

    Press Release Nicox Reaches 50% Enrollment Threshold in U.S. Phase 2 Study with NCX 470 Ahead of Schedule ............................................... January 8,.

  • GlobeNewswire

    VYZULTA Approved in Canada by Nicox's Partner

    Press Release VYZULTA Approved in Canada by Nicox's Partner ............................................... January 4, 2019 - release at 7:30 am CET Sophia Antipolis, France.

  • GlobeNewswire

    Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq

    Encouraging preclinical efficacy data on NO-donating PDE5 inhibitors Focusing of research activities on the most promising new pharmacologic classes Collaboration with Novaliq to access novel formulation technology for these new compounds ............................................... Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it will be focusing its research activities on topical nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitors and soluble guanylate cyclase (sGC) stimulators.  As part of this focus, Nicox has entered into a research collaboration with Novaliq GmbH  for the development of novel topical ophthalmic formulations of Nicox's NO-donating PDE5 inhibitors based on Novaliq's water-free enabling EyeSol® technology, for lowering intraocular pressure (IOP).

  • GlobeNewswire

    Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market

    Accesses the fast-growing Chinese glaucoma market Nicox to potentially receive up to €36.25 million in development and commercial milestones payments, including a €3 million upfront payment Tiered royalties from 6% to 12% on net sales of NCX 470 in the Chinese market Ocumension responsible for all development and commercialization activities in the Chinese market ...............................................

  • GlobeNewswire

    Nicox Postpones NASDAQ Listing Due to Market Volatility

    Press Release Nicox Postpones NASDAQ Listing Due to Market Volatility ............................................... October 30, 2018 - release at 7:30 am.